Anti-NKAI3/ NKAIN3/ FAM77D monoclonal antibody

Anti-NKAI3/ NKAIN3/ FAM77D antibody for FACS & in-vivo assay

Target products collectionGo to NKAIN3/NKAIN3 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0882-Ab-1/ GM-Tg-hg-MP0882-Ab-2Anti-Human NKAIN3 monoclonal antibodyHuman
GM-Tg-rg-MP0882-Ab-1/ GM-Tg-rg-MP0882-Ab-2Anti-Rat NKAIN3 monoclonal antibodyRat
GM-Tg-mg-MP0882-Ab-1/ GM-Tg-mg-MP0882-Ab-2Anti-Mouse NKAIN3 monoclonal antibodyMouse
GM-Tg-cynog-MP0882-Ab-1/ GM-Tg-cynog-MP0882-Ab-2Anti-Cynomolgus/ Rhesus macaque NKAIN3 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0882-Ab-1/ GM-Tg-felg-MP0882-Ab-2Anti-Feline NKAIN3 monoclonal antibodyFeline
GM-Tg-cang-MP0882-Ab-1/ GM-Tg-cang-MP0882-Ab-2Anti-Canine NKAIN3 monoclonal antibodyCanine
GM-Tg-bovg-MP0882-Ab-1/ GM-Tg-bovg-MP0882-Ab-2Anti-Bovine NKAIN3 monoclonal antibodyBovine
GM-Tg-equg-MP0882-Ab-1/ GM-Tg-equg-MP0882-Ab-2Anti-Equine NKAIN3 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0882-Ab-1/ GM-Tg-hg-MP0882-Ab-2; GM-Tg-rg-MP0882-Ab-1/ GM-Tg-rg-MP0882-Ab-2;
GM-Tg-mg-MP0882-Ab-1/ GM-Tg-mg-MP0882-Ab-2; GM-Tg-cynog-MP0882-Ab-1/ GM-Tg-cynog-MP0882-Ab-2;
GM-Tg-felg-MP0882-Ab-1/ GM-Tg-felg-MP0882-Ab-2; GM-Tg-cang-MP0882-Ab-1/ GM-Tg-cang-MP0882-Ab-2;
GM-Tg-bovg-MP0882-Ab-1/ GM-Tg-bovg-MP0882-Ab-2; GM-Tg-equg-MP0882-Ab-1/ GM-Tg-equg-MP0882-Ab-2
Products NameAnti-NKAIN3 monoclonal antibody
Formatmab
Target NameNKAIN3
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NKAIN3 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species NKAI3/ NKAIN3/ FAM77D VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0882
    Target NameNKAIN3
    Gene ID286183,269513,689576,106999785,609791,101085019,788352,100065588
    Gene Symbol and SynonymsC530048M05,E130310K16Rik,FAM77D,NKAIN3,NKAIN3-IT1,UG0898H09
    Uniprot AccessionQ8N8D7
    Uniprot Entry NameNKAI3_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000185942
    Target ClassificationN/A

    The target: NKAIN3, gene name: NKAIN3, also named as FAM77D. NKAIN3 is a member of a family of mammalian proteins (see NKAIN1; MIM 612871) with similarity to Drosophila Nkain (Gorokhova et al., 2007 [PubMed 17606467]).[supplied by OMIM, Jun 2009].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.